Bookmark

Add to MyYahoo RSS

Eisai News

News on Eisai (Ticker: ESALY) continually updated from thousands of sources around the net.

Monday Apr 14 | Applied Clinical Trials

Arena Pharmaceuticals Reports Eisai's Launch of National Television...

Arena Pharmaceuticals Reports Eisai's Launch of National Television Advertising Campaign for BELVIQ? CIV for Chronic Weight Management Arena Pharmaceuticals Reports Eisai's Launch of National Television Advertising Campaign for BELVIQ CIV for Chronic Weight Management /PRNewswire/ -- Arena Pharmaceuticals, Inc. today reported that Eisai Inc. has ... (more)

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Arena Pharmaceuticals, TV Advertising, Food and Drug Administration, Marketing

Tue Apr 08, 2014

BioSpace

Epizyme Granted Patent Covering Diagnosis And Treatment Of Cancers Associated With EZH2 Mutation

8,691,507 with claims that cover the identification of patients carrying EZH2 oncogenic mutations as candidates for treatment with EZH2 inhibitors.

Comment?

Related Topix: Medicine, Cancer, Health, Patent / Trademark Law, Law, Lymphoma, Genetics, Biotech, Healthcare Industry, Sarcoma

Tue Apr 01, 2014

BioSpace

Zalicus Inc.To Present At American Association for Cancer Research 2014 Annual Meeting

Zalicus Inc. , a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that a poster developed in collaboration with colleagues from Eisai Inc. and a podium presentation with collaborators from Sanofi will be given at the American Association for Cancer Research 2014 Annual Meeting ... (more)

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Mon Mar 31, 2014

Business Wire

Press release distribution, EDGAR filing, XBRL, regulatory filings

ETS2101 well tolerated with no serious adverse events. Early evidence of possible hal...

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Eisai Co, AB Electrolux, Appliances

Sys-Con Media

Eisai Assigns Its Worldwide Exclusive License for DACOGENA to Otsuka

We give our first thoughts to patients and their families, and helping to increase the benefits health care provides.

Comment?

Related Topix: Biotech, Medicine, Eisai Co, Healthcare Industry, Marketing

Business Wire

Otsuka Acquires Rights to Hematological Cancer Treatment Dacogen from Eisai

Otsuka has acquired rights from Eisai Inc. to develop and sell in the US, Canada and Japan the DNA methylation inhibitor Dacogen A .

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Eisai Co, Startups, SuperGen, Marketing

•••
•••
•••
•••

Seattle Jobs

•••
•••
•••
•••
•••